Jobs
View more job listings or post a job
Genentech Senior/Principal Scientific Researcher (Cell-based Assay Development), BioAnalytical Sciences Department, Genentech
University of California, Davis PHARMACOLOGY TECHNICIAN (SRA 2, NEX)
Vir Biotechnology Director, Regulatory Affairs
Vir Biotechnology Senior Director, Business Development
Vir Biotechnology Senior Scientist, Host Directed Therapy, Click here to apply
PTC Therapeutics Director, Clinical Pharmacology
Alturas Analytics Quality Assurance Director
MCure Biosciences Scientist or Research Associate
Cytokinetics Director/Senior Director, DMPK
Inotiv Senior Toxicologist / Study Director
Post a job

Symposium

[Free Online Symposium] Oxbryta® (Voxelotor) tablets for Sickle Cell Disease: The R&D Journey and Lessons Learned (jointly by PBSS and CLSA)


Speakers: Mira Pochron PhD (Head of Translational Biology, Global Blood Therapeutics)
Organizers: Dennis Hu, Cyrus Khojasteh and Dewakar Sangaraju (all of Genentech)
Date: 2021-02-16
Time: 12:00-13:30 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor: (1)CLS
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-02-15  (it will close sooner if the seating cap is reached)

About the Topic

Building upon nearly 70 years of research in sickle cell disease (SCD) pathology, voxelotor, an HbS polymerization inhibitor, was developed to treat

the root cause of SCD pathophysiology. In 2019, the FDA granted Oxbryta® (Voxelotor) accelerated approval using hemoglobin, a biologic surrogate endpoint, indicative of reduced SCD hemolysis. In this presentation, we will share the R&D journey of Oxbryta®.


This presentation is part of the symposium series “Success Stories of Recently Approved Drugs and Lessons Learned”, jointly organized by PBSS and CLSA (California Life Science Association, a trade association representing California’s life science industry).


About the Speakers

Mira Pochron, PhD

Staff Scientist, Head of Translational Biology

Global Blood Therapeutics, Inc

Dr. Mira Pochron currently serves as the Head of Translational Biology at Global Blood Therapeutics (GBT). During her tenure at GBT she was an integral part of developing and overseeing the collection of pharmacodynamic data in the phase 1/2a studies with voxelotor and continues to oversee the collection of pharmacodynamic and biomarker data. She has been with GBT since it’s early days in 2011 and been a core team member involved in assay development, compound screening and animal studies with Hb modifiers, such as voxelotor. Dr. Pochron received her Ph.D. in Chemistry and Biochemistry from University of California, Santa Cruz.


2022-07-27, [Free Online Symposium] Success Stories and Lessons Learned from Recent FDA Approvals: VOXZOGO (vosoritide) by BioMarin Pharmaceutical Inc.
2022-08-17, [Free Online Symposium] Advances in Oncology
2022-09-15, [Free Online workshop] Immunogenicity of Biologic Drugs – Clinical Relevance case studies, Predictive Tools & Challenges with New modalities
2022-11-02, [Free Online workshop] Bispecific Antibodies: Discovery, Engineering, Development and Regulatory Considerations
2022-11-14, [Free Online Symposium] Advances in Cell therapy
©Pharmaceutical & BioScience Society, International; Last Modified: 6/27/2022; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Veloxity Labs, LLC The unique employee-owned LC-MS/MS bioanalytical CRO with >100 years of experience and the responsiveness of a start-up! GLP and non-GLP.
Laviana Pharma Corp Laviana’s new GMP facility will be validated very soon! We’re taking bookings for API, Intermediate & Custom Synthesis and R&D services for Q2-2023
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Synthesis, purification & NMR characterization of phase 1 and 2 drug metabolites at mg-g scale with COAs. Also experts in natural products.
Submit a Text Ad